Oppenheimer analyst Matthew Hershenhorn raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $22 from $19 and keeps a Perform rating on the shares. Oppenheimer was impressed by new details and overall strategy shared at Acadia’s inaugural R&D Day, and sees incremental insights as supporting potential longer-term value, the analyst tells investors in a research note. The firm remains cautiously optimistic pending further derisking and appreciates Acadia’s comments on prioritizing R&D efficiency and BD strategy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- ACADIA Pharmaceuticals: Promising Pipeline and Strategic Investments Drive Buy Rating
- ACADIA Pharmaceuticals: Hold Rating Amid Strategic R&D Focus and Competitive Challenges
- Acadia Pharmaceuticals price target raised to $38 from $26 at RBC Capital
- Acadia court ruling supports Nuplazid exclusivity into 2030, says Mizuho
- Acadia Pharmaceuticals Wins Patent Case for NUPLAZID